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Objective.
 
Injection of dendritic cells (DC) engineered with recombinant adenoviral vectors to
produce interleukin-12 (IL-12) inside experimental murine tumors frequently achieves com-
 
plete regressions. In such a system the function of CD8
 

 
 T cells has been shown to be an abso-
lute requirement, in contrast to observations made upon depletion of CD4
 

 
 T cells, which min-
imally affected the outcome. The aim of this work was to study the possible involvement of
natural killer (NK) cells in this setting.
 
Materials, Methods, and Results.
 
Depletions with anti-AsialoGM1 antiserum showed only a
small decrease in the proportion of complete regressions obtained that correlated with induc-
tion of NK activities in lymphatic tissues into which DC migrate, whereas combined depletions
 
of CD4
 

 
 and NK cells completely eliminated the antitumor effects. Likewise in vivo neutraliza-
 
tion of interferon-
 

 
 (IFN-
 

 
) also eliminated those therapeutic effects. Trying to define the cel-
lular role played by NK cells in vivo, it was observed that injection of cultured DC inside the
 
spleen of T- and B-cell–deficient (Rag1
 

 
/
 

 
) mice induced upregulation of NK activity only if
DC had been adenovirally engineered to produce IL-12. In addition, identically transfected fi-
broblasts also activated NK cells, indicating that IL-12 transfection was the unique require-
ment. Equivalent human DC only activated in vitro the cytolytic and cytokine-secreting func-
tions of autologous NK cells if transfected to express human IL-12.
 
Conclusions.
 
Overall, these results point out an important role played by NK cell activation in
the potent immunotherapeutic effects elicited by intratumoral injection of IL-12–secreting
DC and that NK activation under these conditions is mainly, if not only, dependent on
IL-12.  © 2002 International Society for Experimental Hematology. Published by Elsevier
 
Science Inc.
 
Dendritic cells (DC) are populations of professional anti-
gen-presenting cells that are being used to elicit antitumor
immune responses both in rodents and in humans [1–3].
Functionally, DC can progress from an immature state in
which they take up and process antigens efficiently but acti-
vate T cells poorly, to a mature state in which such features
are inverted [1,4]. Maturation is induced by proinflamma-
tory cytokines or certain microbe components [1]. A thera-
peutically potent treatment fashion is to introduce those
cells by direct injection into experimental tumors. Such an
approach is only successful if DC are transfected to express
interleukin (IL)-12 [5,6], IL-7 [7], IL-2 [8], or CD40L [9],
with the condition that DC share MHC antigen–presenting
molecules with the tumor-bearing animals [5]. DC capture
antigens from the malignant tissue, possibly by multiple but
still ill-defined mechanisms [10–15], and promptly migrate
to lymph nodes where they present tumor antigens to T cells
[16]. In the case of DC-secreting IL-12, high production of
IFN-
 

 
 at this location as well as the induction of potent tu-
mor-specific CTL activity has been documented [6].
Interleukin-12 was identified as a factor that activates the
function of natural killer (NK) cells [17,18]. NK cells ex-
press receptors for IL-12 and when stimulated with this cy-
tokine potently upregulate their functions [19], as it has been
also observed in vivo in human cancer patients treated sys-
temically with this protein [20]. It is possible that IL-12 acts
not only by increasing the level of expression of effector
molecules such as perforin and granzymes [17,18,21,22],
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but also by controlling the function or the expression of re-
ceptors triggering cytotoxicity [23]. Besides the elegant
mechanisms that regulate whether or not engagement with a
target cell causes its destruction in vitro [24–26], little is
known about the real functions of NK cells in vivo. NK-
deficient mice are largely normal [27], and observations in
the limited number of patients with congenital NK deficiency
only suggest that these cells are involved in the immune re-
sponse against herpes viruses [28,29]. Their involvement in
tumor immunity is controversial, although their contribution
in experimental immunotherapy in certain mouse models
has been revealed by specific depletion with antibodies
[17,30–32].
DC have been reported to regulate NK functions [33],
and IL-12 production by DC seems to be the key event at
regulating NK, cytotoxic T-lymphocytes (CTL), and Th1
responses [17,19]. The upregulation of NK functions that
has already been seen in vitro with mature DC requires di-
rect DC-NK contact [33] with the involvement of IL-12 and
IL-18 [34]. We show that immature DC, such as those used
for intratumoral injection [5,6], do not upregulate NK func-
tions unless transfected with IL-12 and that cultured DC en-
gineered to produce IL-12 potently activated NK cells both
in vivo and in vitro. We report a reduction of antitumor ac-
tivity when NK cells are depleted, probably explained by loss
of NK functions upregulated by DC-secreting IL-12. More-
over, complete loss of the therapeutic effect by simultaneous
depletion of NK and CD4
 

 
 T cells point out an activity
shared by both lymphocyte subsets that is absolutely required
to induce antitumor effects and that is activated by IL-12.
 
Materials and methods
 
Mice and cell lines
 
BALB/c, C57BL/6, and Rag1
 

 
/
 

 
 in C57Bl/6 background mice
were obtained from Harlan (Barcelona, Spain), and used between
6 and 18 weeks of age. Rag1
 

 
/
 

 
 mice were bred in our animal fa-
cility.
MC38 and CT26 are colon adenocarcinomas of C57BL/6 and
BALB/c origin, respectively [5]. YAC-1 is a NK cell–sensitive
T-cell lymphoma of A/Sn background [31]. The HLA-negative
erythroleukemia K562 was purchased from American Type Cul-
ture Collection (ATCC, Rockville, MD, USA) and the MHC class
I–deficient 721.221 B-LCL was obtained from Dr. López-Botet
(Hospital de la Princesa, Madrid, Spain). IZA-1 is an SV40-
T-transfected immortalized fibroblast line of BALB/c origin [5].
Cells were maintained in RPMI 1640 medium with 2 mM L-gluta-
mine, 100 U/mL streptomycin, 100 
 

 
g/mL penicillin, and 100 
 

 
g/mL
cyprofloxacin, and supplemented with 10% heat-inactivated fetal
calf serum (FCS). All cell culture reagents were from Gibco
(Basel, Switzerland).
 
Tumor model and in vivo experiments
 
For treatment of tumor-bearing mice in vivo, BALB/c mice were
inoculated subcutaneously in the right flank with 4 
 

 
 10
 
5
 
 CT26
cells. On day 7, tumors were treated and thereafter growth was
measured weekly [5].
For intrasplenic injections, Rag1
 

 
/
 

 
 mice under general anes-
thesia underwent laparotomy and 2 
 

 
 10
 
6
 
 DC (in 50 
 

 
L) were in-
jected inside the spleen with a 28G syringe.
 
CD4
 

 
 T-cell and NK-cell depletion
 
L3T4 (CD4
 

 
)-specific rat anti-mouse antibody was obtained as as-
citic fluid in nude mice of the hybridoma GK1-5 (ATCC). Deple-
tion of NK cells was accomplished by administration of a rabbit
anti-AsialoGM1 antiserum (Wako, Germany). Both antibodies
were administered intraperitoneally at a dose of 100 
 

 
L per dose
on day 
 

 
2, on day 
 

 
1, before dendritic cell administration, and
every 7 days thereafter as previously described [35]. Cell-deple-
tion activity by these antibodies has been tested for every batch by
FACS in the spleen of control mice. In vivo neutralization of IFN-
 

 
 was achieved by intraperitoneal injection of ascitic fluid of the
hybridoma R4-6A2 (ATCC).
 
Cytokines and reagents
 
Recombinant human IL-4 was obtained from PeproTech (London,
UK), and recombinant human granulocyte-macrophage colony-stim-
ulating factor (GM-CSF) (Leucomax) was from Novartis (Basel, Swit-
zerland). Recombinant mouse IL-4, recombinant murine GM-CSF, re-
combinant human IL-12, and tumor necrosis factor-
 

 
 (TNF-
 

 
) were
from Peprotech and anti-human IL-12 and anti-mouse IL-12 were ob-
tained from PharMingen (San Diego, CA, USA). Polyclonal rat IgG
was purchased from Sigma (Madrid, Spain).
 
Culture of murine dendritic cells
 
The method for generation of DC from bone marrow has been pre-
viously described [36]. Cells were cultured for seven days in 12-
well plates (Reactiva, Barcelona, Spain) at 10
 
6
 
/mL in RPMI-1640
medium (Gibco) supplemented with 100 U/mL penicillin (Life
Technologies), 100 
 

 
g/mL streptomycin, 2 mM glutamine, 10%
fetal bovine serum (Gibco), 10 
 

 
g/mL cyprofloxacin (Vita, Barce-
lona, Spain), 20 ng/mL rmIL-4 (PeproTech), and 20 ng/mL
rmGM-CSF (PeproTech). After 3 and 5 days of culture nonadher-
ent cells were removed and fresh medium with cytokines was
added. On day 7, cells in suspension and loosely adherent cells
were collected.
 
Culture of human dendritic cells
 
Peripheral blood mononuclear cells (PBMC) were isolated from
buffy-coats of healthy donors obtained from the Blood Bank of
Navarra in Pamplona (Spain) by Ficoll density-gradient centrifu-
gation (Ficoll-Hypaque, Pharmacia, Uppsala, Sweden). Cells from
the light-density fraction were enriched with anti-CD14 magnetic
beads (Miltenyi Biotech, Bergisch Gladbach, Germany) according
to manufacturer’s protocols. CD14
 

 
 cells were cultured in 6-well
plates (Costar) at a density of 10
 
6
 
 cells/mL in the presence of
rhGM-CSF (100 ng/mL) and rhIL-4 (100 ng/mL) in RPMI1640
medium (Gibco) supplemented with 10% FCS (Gibco) and with
antibiotics (100 U/mL penicillin, 100 
 

 
g/mL streptomycin, 10 
 

 
g/
mL cyprofloxacin). Fresh media and cytokines were replenished
every 2 days according to previously reported protocols [37].
 
Generation of human CD56
 

 
 cells
 
PBMC were isolated by centrifugation on Ficoll-Hypaque (Phar-
macia) density gradient from autologous normal donor buffy-
coats. Mononuclear cells were incubated with magnetic beads
coated with anti-CD56 antibodies (MACS, Miltenyi Biotech) and
were enriched using positive selection columns as described
above. CD56
 

 
 cells were employed immediately or were main-
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tained frozen in 10% dimethylsulfoxide (DMSO)-containing FCS.
Coculture of CD56
 

 
 cells with DC was carried out in U-bottom
96-well plates (Costar) at the indicated NK:DC ratios.
 
Recombinant adenovirus production and adenovirus infection
 
The construction of a recombinant adenovirus carrying either mu-
rine or human IL-12 (AdCMVmIL-12/AdCMVhIL-12) has been
previously reported [38 and C. Qian et al., manuscript in prepara-
tion). Adenovirus carrying 
 
lacZ
 
 (AdCMVLacZ) reporter gene has
also been reported [39]. Purified viruses were extensively dialyzed
against 10 mM Tris, 1 mM MgCl
 
2
 
 and stored in aliquots at 
 

 
80
 

 
C.
Plaque-forming units (pfu) were determined by repeated cyto-
pathic plaque assays on 293 cells and contamination with compe-
tent adenovirus was excluded by lack of lytic infection of a panel
of E1
 

 
 cells.
DC were infected on day 7 of culture. Briefly, cells were recov-
ered, washed, and incubated with the adenoviruses at the indicated
multiplicities of infection (MOIs) in serum-free medium (5 
 

 
 10
 
6
 
cells/500 
 

 
L). After 1 hour at 37
 

 
C, complete medium was added
(1 mL/10
 
6
 
 cells).
 
Immunofluorescence and flow cytometry
 
Expression of surface markers was determined by flow cytometry
(FACScalibur, Becton-Dickinson, San Jose, CA, USA). After cul-
ture, either DCs or NK cells were washed and labeled with FITC,
PE, or PerCP-conjugated mouse anti-human mAbs (Becton-Dick-
inson), antiCD11c, antiCD14, antiCD3, and antiCD56 for 30 min-
utes at 4
 

 
C. Nonreactive fluorochrome-tagged mouse mAbs were
used as controls (Becton-Dickinson).
DC cultures were FITC-labeled with PKH2 (Sigma) according
to manufacturer’s instructions and fluorescence microphotographs
were taken with a conventional microscope equipped with a UV
lamp (Nikon).
 
Cytotoxicity assays
 
Cytotoxicity was assessed by standard 4 h 
 
51
 
Cr-release assays [40].
 
Cytokine quantitation by ELISA
 
Human IFN-
 

 
 and IL-12 (OptiEA, PharMingen) and mouse IFN-
 

 
(Cytoscreen, Biosource, Belgium) concentrations were assessed
by enzyme-linked immunoabsorbent sandwich assay (ELISA) ac-
cording to manufacturers’ instructions.
 
Results
 
NK cells play a role in the therapeutic
efficacy of intratumorally injected DC producing IL-12
 
Intratumoral injections of bone marrow–derived DC
(BMDC) adenovirally engineered to produce IL-12 eradi-
cate a proportion (50–80%) of experimental colon carcino-
mas, including those derived from subcutaneous injection of
CT26 and MC38 tumor cell lines. For those experiments
immature DC were employed. The use of immature DC was
preferred since artificially released BMDC inside malignant
tissue had to uptake and efficiently process tumor antigens
and subsequently migrate to lymph nodes. Antitumor ef-
fects required the expression of syngenic MHC molecules
on DC and the activity of CD8
 

 
 T cells [5]. By contrast, de-
pletion of CD4
 

 
 T cells did not impair the ability of the pro-
 
cedure to induce regressions of CT26 tumors [5]. In this
study (Fig. 1), we observe that depletion of AsialoGM1
 

 
cells resulted in a moderate reduction of tumor regressions
of subcutaneous CT26-derived experimental malignancies
achieved by intratumoral injection of AdCMVIL-12–engi-
neered BMDC (10 out of 15 vs 7 out of 15 cases). In addi-
tion, there was a nonstatistically significant tendency to a
delay (approximately 1–2 weeks) in the time elapsed from
treatment on day 7 to the beginning of tumor shrinkage in
those mice depleted with anti-AsialoGM1, which eventually
underwent tumor eradication (Fig. 1). It was confirmed that
depletion of CD4
 

 
 T cells with specific mAb did not mod-
ify the efficacy (Fig. 1). With these experimental results, it
seemed that NK cells played only a minor role but, surpris-
ingly, simultaneous depletion of AsialoGM1
 

 
 and CD4
 

 
lymphocytes almost completely eliminated the antitumor
activity induced by a single intratumoral injection on day 7
of tumor growth with 5 
 

 
 10
 
5
 
 BMDC transfected with Ad-
CMVIL-12 (Fig. 1).
Besides, mAb blocking IFN-
 

 
 function completely elim-
inated the therapeutic effect if given to 6 mice treated intra-
Figure 1. Combined depletion of CD4 and AsialoGM1 lymphocytes
abrogates antitumor effects elicited by intratumoral injection of DC trans-
fected with AdCMVmIL-12. Growth of CT26-derived experimental
tumors in BALB/c mice that were injected intraperitoneally with the indi-
cated depleting antibodies or control rat IgG on days 5, 6, 7, 14, and 21
after tumor inoculation. All mice were treated with a single intratumoral
injection of 5  105 BMDC transfected with AdCMVmIL-12 on day 7
after tumor cell challenge. Control and double-depleted groups were statis-
tically different with a p 	 0.027 according to Fisher exact test. Efficacy of
depletion was monitored by FACS analysis of peripheral blood mononu-
clear cells in identically treated mice (data not shown). Fraction of tumor-
free mice at week 12 has been included in each panel.
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tumorally with IL-12–producing DC (Fig. 2). Those results
are consistent with a major role of CTL induction in this
type of immunotherapy, as well as with the prominent role
of IFN-
 

 
 as a downstream mediator of most of the effects of
IL-12 [17]. We have confirmed, as previously reported by
others [6,16], that FITC-labeled DC injected into a subcuta-
neous tumor migrate to draining lymph nodes with high in-
tensity (Fig. 3a). Moreover, some degree of migration was
also found both into contralateral inguinal lymph nodes and
into the spleen (M. Duarte et al., manuscript in preparation).
We have also found that intratumoral injection of IL-12–engi-
neered DC elicits some IFN-
 

 
 production in the draining
lymph node that is partly inhibited by AsialoGM1
 

 
 depletion
(Fig. 3b). This result indicates that secretion of IFN-
 

 
 under
these conditions is in part mediated by NK cells, and it is
consistent with the observation of a slight upregulation of NK
cytolytic activity against YAC-1 in lymph node cells that is
abolished by anti-AsialoGM1 treatment (Fig. 3c). Surpris-
ingly, the increase in NK activity was higher in splenocytes
than in the cells from draining lymph nodes of the same
mice (Fig. 3c). This could be related to the relative higher
proportion of DX5
 

 
 NK cells in the spleen in comparison to
lymph nodes as observed in control mice (not shown). It is
unknown whether NK activity is elicited by those barely de-
tectable migrating DC into the spleen or by a cytokine cas-
cade provoked by DC producing IL-12 outside the spleen.
 
AdCMVIL-12–engineered BMDC activate NK
functions in vivo through a mechanism dependent on IL-12
 
In order to investigate whether BMDC engineered to pro-
duce IL-12 activated NK functions in vivo, experiments
were carried out by direct intrasplenic injection of 2 
 

 
 10
 
6
 
BMDC in Rag1
 

 
/
 

 
 C57BL/6 mice. These mice lack both T
and B cells. Hence, NK cells represent the only lymphoid
population remaining in their spleens.
Figure 2. Inhibition of IFN- function eliminates the efficacy of intratu-
morally injected DC secreting IL-12. Number of tumor-free surviving ani-
mals from two groups of BALB/c mice that received 105 DC transfected
with AdCMVIL-12 and injected inside CT26-derived subcutaneous tumors
implanted 6 days earlier. Mice received, as indicated in the figure, on day 7
and 14 after tumor cell challenge 100 L of ascites containing anti–IFN-
neutralizing mAb or control antibody. Statistical difference according to
log-rank test was p 
 0.01.
Figure 3. Intratumoral injection of IL-12–transfected DC enhances NK
functions in lymphoid tissue. (a) Migration of DC assessed by a representa-
tive microscopic field (200) of the draining lymph node from three mice
bearing subcutaneous CT26 tumors that received an intratumoral dose of
5  105 AdCMVmIL-12–transfected DC, which had been FITC-labeled
prior to injection. Absence of fluorescence background in mice intratumor-
ally injected with saline was negible. (b) IFN- concentration (mean 
SEM) assessed by ELISA in 24-hour supernatants from lymph node cell
suspensions (5  105/mL) derived from CT26 tumor-bearing BALB/c
mice (three mice per group) that had been treated with intratumoral injec-
tions of HBSS, nontransduced DC, or IL-12–transduced DC with or with-
out simultaneous depletion of AsialoGM1 cells. For statistical analysis
data from multiple experiments have been pooled and results found to be
statistically different (p 
 0.01) for DC vs DCIL-12 according to two-
tailed Student’s t-test. (c) Cytolytic activity against NK-sensitive YAC-1
cell line detected in draining lymph nodes and in the spleen of CT26
tumor-bearing mice treated as in (b); Effector cells were harvested and
pooled from three mice per group 48 hours after intratumoral treatment
with DC. Using results from pooled repeated experiments, the groups with
AdCMVIL-12–transfected DC were found to be statistically different (p 

0.05) using Mann-Whitney’s U-test.
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Spleen cells from mice that had received, 24 hours earlier,
a single intrasplenic injection of BMDC transfected with Ad-
CMVIL-12, augmented their cytolytic activity against the
NK-sensitive YAC-1 lymphoma and the syngenic NK-resistant
MC38 colon carcinoma (Fig. 4a). By contrast, such an effect
was not found when BMDC had been transfected with a con-
trol adenovirus encoding for 
 

 
-galactosidase (AdCMVLacZ)
(Fig. 4a). In order to find out whether the observed NK-acti-
vating properties were exclusively due to IL-12 secretion or
whether other molecules expressed by DC were contributing
to the effect, we performed similar experiments, injecting
transfected fibroblasts instead of DC. To do so, we used
equal numbers of the SV40T-transformed fibroblast cell
 
line IZA-1 [5] identically transfected with AdCMVIL-12.
Our data clearly show that IL-12–transfected IZA-1 upregu-
lated NK function to a similar extent as IL-12-BMDC did
(Fig. 4b). It is noteworthy that the level of IL-12 p70 output
in vitro by transfected fibroblasts was comparable to equally
transfected BMDC [5]. It is also worth remembering that we
have previously reported that intratumoral injection of Ad-
CMVIL-12–transfected IZA-1 did not exert any antitumor
activity [5] or induce detectable antitumor CTL.
 
Human immature, monocyte-derived DC
augment NK activities in vitro only if transfected with
an adenovirus encoding for human IL-12 (AdCMVhIL-12)
 
The results obtained by intrasplenic injections in the murine
system could not be obviously confirmed as such in hu-
mans, so in vitro cocultures of DC and NK cells of human
origin were performed to address this issue.
Human NK cells were obtained as described above
achieving up to 95% purity encompassing 
 

 
80% CD3
 

 
CD56
 

 
 and 15% CD3
 

 
CD56
 

 
 lymphocytes (Fig. 5a). Hu-
man DC were derived from CD14
 

 
 immunomagnetically
selected cells by 7-day culture with GM-CSF  IL-4. Re-
sulting cells were CD14CD11c as shown in Figure 5b.
As shown in Figure 6a, human monocyte–derived DC
transfected with an adenovirus carrying both chains of hu-
man IL-12 (AdCMVhIL-12) (MOI 1000) produced impor-
tant quantities of IL-12 heterodimer (p70), in contrast to un-
transfected DC or DC transfected with a control adenovirus.
Figure 4. AdCMVmIL-12–engineered DC activate NK functions in vivo
through a mechanism dependent on IL-12. (a) Rag1/ C57BL/6 mice (three
per group) received an intrasplenic injection of AdCMVmIL-12–transfected
DC, AdCMVLacZ-transfected DC, or untransfected DC (2  106 cells).
Similar mice were injected with saline buffer as a control. 24 hours later
splenocytes were tested for cytolytic activity in a standard 51Cr-release
assay against YAC-1 and MC38 cell lines at the indicated effector:target
ratios. (b) Rag1/ mice were treated with a single intrasplenic injection of
either AdCMVmIL-12–transfected DC, IL-12–transfected fibroblast cell
line (IZA-1), or their untransfected counterparts (2  106 cells in every
case). A control group of similar mice received a single intrasplenic injec-
tion of saline buffer. Splenocytes were assessed 24 hours later for cytolytic
activity against YAC-1 and MC38 cell lines. In vitro levels of IL-12 p70
output by transfected fibroblasts were comparable to equally transfected
DC (not shown). Results are representative of three independent experi-
ments similarly performed. Using results of the group of DC or fibroblasts
transfected with IL-12, they were found to be statistically different (p 

0.05) than the other groups using Mann-Whitney’s U-test.
Figure 5. Enrichment of human NK cells and culture of monocyte-derived
human DC. (a) CD56 cells were purified by magnetic beads yielding 79%
of CD3CD56 cells as assessed by double immunostaining and flow
cytometry. (b) Immunostaining and FACS analysis of CD14 cells puri-
fied from human PBMC by immunomagnetic beads and cultured for 7 days
in the presence of GM-CSF and IL-4.
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At this point it is worth mentioning that we and others have
previously reported moderate changes in surface molecules
towards maturation in adenovirally transfected DC [41,42].
It was observed that cytotoxicity against K562 and
721.221 target cells augmented after 24-hour coculture of
CD56 lymphocytes and DC (NK:DC 	 4:1, 2:1, and 1:1).
Such an effect was not sustained if DC had not been trans-
fected with AdCMVhIL-12 and only marginally if trans-
fected with a control adenovirus (AdCMVLacZ) (Fig. 6b).
In addition, IFN- secretion was observed only when DC
had been transfected with AdCMVhIL-12 but not with a
control adenovirus (Fig. 6c).
These results lead to the conclusion that IL-12 is the
main NK-stimulating factor in this setting. This is further
Figure 6. Human monocyte–derived DC augment NK activity in in vitro
coculture only if they have been engineered to produce IL-12. (a) IL-12
p70 concentration (mean  SEM) assessed by ELISA at 48 hours in super-
natants of human immature DC (1  106/mL) left untransfected or trans-
fected with LacZ or IL-12 genes. (b) Human DC, cultured for 7 days from
purified CD14 PBMC, were left untransfected or transfected either with
LacZ or human IL-12 genes by recombinant adenoviruses, and subse-
quently cocultured with CD56 lymphocytes. 24 hours later, cytolytic
activity of cocultures against K562 and 721.221 human leukemia cell lines
was comparatively assayed in standard 51Cr-release assays. Data are repre-
sentative of five experiments similarly performed. For statistical analysis
data from experiments have been pooled and results found to be statisti-
cally different (p 
 0.05), as indicated (*) for DC vs DCIL-12 according to
Mann-Whitney’s U-test. (c) IFN- concentration (mean  SEM) quanti-
fied by ELISA in 24-hour supernatants from cocultures of DC and CD56
cells as described in (b) that were performed at the indicated NK:DC ratios.
Figure 7. IL-12 as a purified protein and DC transfected with IL-12
enhance NK activity of CD56 lymphocytes with similar intensity. (a)
Interleukin-12 as a recombinant protein (1 ng/mL) was added to cultures of
CD56 cells in parallel to the coculture of IL-12–transfected DC with
CD56 lymphocytes. 24 hours later cells were tested for their cytolytic activ-
ity against the 721.221 cell line. (b) Addition of 5 g/mL of anti–IL-12 p40
neutralizing antibody inhibited the increase of cytolytic activity against
K562 cells of CD56 lymphocytes that had been cocultured with AdCM-
VIL-12–transfected DC. Results are the mean of triplicate assays in which
SD was less than 10%. Polyclonal rat IgG was used as a control (5 g/mL).
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supported by experiments with human recombinant IL-12
added to the cultures of CD56 lymphocytes as a purified
protein (1 ng/mL) that augmented NK activity in a compa-
rable fashion to coculture with AdCMVhIL-12–transfected
human DC (Fig. 7a). In addition, the induction of cytolytic
activity by DC-producing IL-12 in coculture with CD56
cells was markedly, albeit not completely, inhibited by neu-
tralizing anti–IL-12 mAb (Fig. 7b).
Human immature DC augment
in vivo mouse NK activity when transfected
with murine IL-12 but not with human IL-12
In an experimental setting of intrasplenic injections in
Rag1/ mice, as the one shown in Figure 3, human DC
were also tested to see whether they upregulated NK func-
tions. To address this issue, monocyte-derived DC were
transfected either with AdCMVmIL-12 or with AdCM-
VhIL-12. It should be noted that human IL-12 fails to dis-
play activity on murine cells [17] and this fact let us assess
whether IL-12 secretion was the unique requirement in the
system. It was found that cytolytic activity in injected
spleens against YAC-1 and MC38 was only significantly in-
creased by DC-producing murine but not human IL-12 (Fig.
8). These results strongly suggest that IL-12 operates by di-
rectly increasing NK functions rather than through auto-
crine loops involving DC themselves. Such a possibility is
ruled out by the fact that IL-12R on human DC is not sensi-
tive to mouse IL-12.
Discussion
Interleukin-12 was originally identified as a cytokine upreg-
ulating NK functions [17]. In fact, T and NK lymphocytes
express the 12-heterodimer receptor for this cytokine, and
importantly, IL-12 elicits strong antigen-independent secre-
tion of IFN- from such cells [22]. DC also express a func-
tional alternative form of the IL-12 receptor that signals in a
different way [43].
To dissect out the cellular and molecular mechanisms of
the impressive antitumor efficacy shown by intratumoral in-
jection of IL-12–transfected DC [5,6], classical antibody
depletions were performed. Treatment with anti-
AsialoGM1, a polyclonal antiserum selective for NK and
NK-T cells, slightly decreased the efficacy of intratumoral
injection of IL-12–secreting BMDC. It had been previously
reported that in that precise model, CD8 T cells played an
absolutely necessary role whereas depletion of CD4 cells
did not impair tumor regressions [5]. In this study we report
that simultaneous depletion of CD4 and AsialoGM1 lym-
phocytes abrogates the tumor-eradicating immune response.
Under these conditions, T-helper, NK, and NK-T cells are
eliminated. It should be noted that intratumorally injected
DC express neither CD4 nor AsialoGM1 and hence cannot
be depleted by those antibodies.
These results indicate that a certain activity that might be
performed either by NK or by T-helper cells is required for
the antitumor effects. What could it be? Our results, clearly
showing that blocking in vivo IFN- activity by neutraliz-
ing mAb eliminates antitumor efficacy, together with the
observations by Nishioka et al. [6] on the production of
IFN- in the lymphoid organs after intratumoral injection of
IL-12–secreting BMDC, indicate that early antigen-inde-
pendent IFN- production by at least one of those cellular
sources (CD4 or NK cells) is indispensable to achieve tu-
mor regression. Our data upon depletion of AsialoGM1
cells support a role for NK cells in that early IFN- secre-
tion that is shown to correlate with a slight increase in their
lytic activity.
It has been recently reported that NK-T cells could be
key players in this system as they have been involved in IL-
12–mediated therapy of liver metastasis [44]. We have not
explored that possibility, but experiments are to be con-
ducted using NK-T–deficient mice [44], and it remains for-
mally possible that our observations upon depletion with
anti-AsialoGM1 are dependent on this NK-T subpopulation.
However NK-T cells are quite selectively located in the
liver and their involvement in immunotherapy has only
been demonstrated for experimental hepatic metastasis [44].
NK involvement in antitumor immunity has been proved
for acute exposure to artificially transferred malignant cells
[45], but not so clearly in other settings. In immunotherapy,
endogenous NK cells have been found necessary when us-
ing IL-12 as a protein [32] or as transfected gene, but it
should be noted that their involvement is found in some
models but not in others [17,21,46,47]. A role for those
lymphoid NK subpopulations has also been found in other
immunotherapeutic approaches such as in the transfection
of CD80 into melanoma cells [30] or in the treatment with
Figure 8. Human DC activate murine splenic NK cells only if transfected to
produce murine but not human IL-12. Rag1/ C57BL/6 mice (three per
group) received intrasplenic injections of 2  106 BMDC transfected with
either human or murine IL-12 genes by recombinant adenoviruses (AdCM-
VhIL-12 or AdCMVmIL-12 as indicated). 24 hours later splenocytes were
tested for cytolytic activity in a standard 51Cr-release assay against YAC-1
and MC38 cell lines. Results are representative of three independent experi-
ments similarly performed. For statistical analysis data from experiments
have been pooled and results found to be statistically different (p 
 0.01) for
DChumanIL-12 vs DCmurineIL-12 according to two-tailed Student’s t-test.
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immunostimulating anti–4-1BB mAb [31]. Although the
molecular sequence of events in which NK cells are in-
volved is not well understood, it is doubtful that the main
function carried out by NK cells could be mere tumor de-
struction by direct cytotoxicity, and it has been postulated
that what NK cells really do is an early secretion of proin-
flammatory mediators required for a subsequent CTL re-
sponse.
Direct cross-talk of DC and NK cells has been proposed.
Initial observations came from the fact that NK cells are in-
volved in the antitumor effects elicited by treatment with
Flt3L [33]. This molecule induces not only the accumula-
tion of dendritic cells infiltrating tumors and the induction
of CTL [48], but also a marked augment on NK activity
[33,49]. Using a mature human DC line, it was shown that
those human DC could activate mouse NK cells to acquire
cytolytic activity and IFN- secretion capacity [33]. The
molecular mechanism, according to this previous report, in-
volves close membrane-to-membrane contact [33]. It is
worth mentioning in this regard that functionally inducible
membrane-associated IL-12 on DC has been reported [50].
DC-NK cross-talk through cytokines has been recently con-
firmed with human DC and NK cells derived in vitro from
cord blood CD34 cells [34]. In this case an involvement of
IL-12, IL-18, and possibly IFN- produced by DC was un-
raveled, showing also a possible role of DC-expressed CD40
acting through an unknown counterreceptor on NK cells
distinct from CD40L [34]. In both pieces of work, DC were
matured with TNF- prior to exposure to NK cells. In our
system, we also found moderate upregulation of NK functions
by DC if they had been matured with TNF- (not shown) but
not if left immature. In the present study we have used a
novel system to analyze the effects of DC in vivo by direct
injections into the spleen of B- and T-cell–deficient mice
that has been very informative on these issues. With these
experiments, it was found that when immature DC are used
by intrasplenic injection or in in vitro coculture, they do not
activate NK cells. Under our conditions, NK activation was
induced strictly and directly by IL-12.
The most relevant findings of this study are that 1)
AsialoGM1 cells play an important role in tumor rejec-
tions elicited by immature IL-12–producing DC injected in-
side malignant tissue, and that 2) immature DC can activate
NK functions both in vivo and in vitro only if they have
been previously gene-modified to produce IL-12. Interest-
ingly, as mentioned before, IL-12–producing fibroblasts in-
jected in the spleen of Rag1/ mice also upregulated NK
functions but failed to induce tumor regressions if injected
intratumorally in the same range of doses [5]. The main dif-
ference between those cell types in this regard is that
BMDC, in contrast to fibroblasts, intensely migrate from
tumor to lymphoid tissue [16]. It can be inferred from our
results that we have experimentally bypassed the need for
migration by direct intrasplenic injections. In addition, fi-
broblasts perform poorly as antigen-presenting cells [51],
although this point has been the matter of some debate in
the past [52] and some efficacy has been found by peritu-
moral injection of IL-12–secreting fibroblasts [53] and con-
firmed in a recent clinical trial.
Dissecting out the intimate mechanisms involved in intra-
tumoral gene therapy with DC engineered to produce IL-12
might be difficult. NK activation joins now the already-
known requirements of tumor antigen uptake, DC migration
to lymphoid organs, and the orchestration of a potent CTL-
mediated immune response as recently suggested [5,6,11,54].
The role of NK cells could be double either through early
cytotoxicity causing release of tumor antigens, thus making
them available for DC-mediated presentation, or through
proinflammatory cytokine/chemokine secretion, as found in
this study, by the AsialoGM1-sensitive production of IFN-
detected in lymphocytes from explanted draining lymph
nodes. If this is the case, artificial potentation of both NK
activities could enhance the efficacy achieved by this prom-
ising DC-based immunotherapeutic approach, which is en-
tering clinical trials at our institution and elsewhere.
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